We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$531M
AUM Growth
-$19.6M
Cap. Flow
-$36.7M
Cap. Flow %
-6.9%
Top 10 Hldgs %
30.22%
Holding
139
New
9
Increased
20
Reduced
40
Closed
15

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$8.09M
2
SYK icon
Stryker
SYK
+$5.81M
3
AMSG
Amsurg Corp
AMSG
+$5.72M
4
ABMD
Abiomed Inc
ABMD
+$5.69M
5
HOLX
Hologic
HOLX
+$5.45M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$6.82M
2
BDX icon
Becton Dickinson
BDX
+$6.76M
3
BIIB icon
Biogen
BIIB
+$5.81M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$4.91M
5
INSY
Insys Therapeutics, Inc.
INSY
+$4.49M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
101
DELISTED
Alder Biopharmaceuticals
ALDR
$824K 0.16%
33,000
– –
ENDP
102
DELISTED
Endo International plc
ENDP
$811K 0.15%
52,000
-119,000
-70% -$2.47M
BIB icon
103
ProShares Ultra NASDAQ Biotechnology
BIB
$84.1M
$796K 0.15%
20,500
+2,500
+14% +$108K
QTNT
104
DELISTED
Quotient Limited Ordinary Shares
QTNT
$775K 0.15%
2,500
– –
CLDX icon
105
Celldex Therapeutics
CLDX
$2.77B
$702K 0.13%
10,667
– –
KITE
106
DELISTED
Kite Pharma, Inc.
KITE
$700K 0.13%
14,000
– –
UTHR icon
107
United Therapeutics
UTHR
$22.7B
$667K 0.13%
6,300
-13,000
-67% -$1.45M
TMH
108
DELISTED
Team Health Holdings Inc
TMH
$610K 0.11%
15,000
– –
CYH icon
109
Community Health Systems
CYH
$465M
$603K 0.11%
50,000
-161,556
-76% -$2.37M
NVRO
110
DELISTED
NEVRO CORP.
NVRO
$553K 0.1%
7,500
– –
RMD icon
111
ResMed
RMD
$28.9B
$506K 0.1%
8,000
– –
PODD icon
112
Insulet
PODD
$11.4B
$454K 0.09%
15,000
– –
MYGN icon
113
Myriad Genetics
MYGN
$584M
$428K 0.08%
14,000
– –
ESPR
114
DELISTED
Esperion Therapeutics
ESPR
$395K 0.07%
40,000
– –
PEN icon
115
Penumbra
PEN
$12.5B
$298K 0.06%
5,000
-3,000
-38% -$162K
THC icon
116
Tenet Healthcare
THC
$16.8B
$276K 0.05%
10,000
– –
SGRY icon
117
Surgery Partners
SGRY
$2.09B
$269K 0.05%
15,000
+5,000
+50% +$74.4K
TBPH icon
118
Theravance Biopharma
TBPH
$877M
$259K 0.05%
11,428
+180
+2% +$3.89K
HTWR
119
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$220K 0.04%
3,813
-1,187
-24% -$38.8K
INFI
120
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$213K 0.04%
160,000
– –
QHC
121
DELISTED
Quorum Health Corporation
QHC
$134K 0.03%
+12,500
New +$146K
LRMR icon
122
Larimar Therapeutics
LRMR
$384M
$120K 0.02%
1,667
– –
TTPH
123
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$95K 0.02%
1,100
– –
EIGR
124
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$66K 0.01%
111
– –
ABUS icon
125
Arbutus Biopharma
ABUS
$901M
– –
-125,000
Closed -$516K
2 3 4
5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2016 Portfolio in Review

As of Q2 2016, Bellevue Group held 139 positions worth $531M, down 3.6% from $551M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group withdrew a net $36.7M in Q2 2016, closing 15 positions and reducing 40 holdings. Its most notable exit was Insys Therapeutics, Inc., an estimated $4.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

Against the trend, Bellevue Group opened a new position in Allergan plc worth $8.11M.

  • Bellevue Group's largest Q2 2016 buy was Allergan plc: 35,100 shares worth $8.11M.
  • Bellevue Group added most to Stryker in Q2 2016, an estimated $5.81M increase.
  • Bellevue Group's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $6.82M.
  • Bellevue Group fully exited Insys Therapeutics, Inc. in Q2 2016, selling an estimated $4.49M.
  • Bellevue Group's ten largest holdings make up 30% of its $531M portfolio in Q2 2016.
  • Bellevue Group opened 9 new positions and closed 15 in Q2 2016.
  • Bellevue Group's portfolio value fell 3.6% quarter-over-quarter to $531M.

Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.